EGI.L Regulatory News (EGI)

Electrical Geodesics, Inc.

Launch of next generation, CE marked, GES 400 series of EEG products

on EGI's ADAPT technology platform

EUGENE, OREGON, US, 17 May 2013 - Electrical Geodesics, Inc. ("EGI" or the "Company"), a leading neurodiagnostic medical technology company, today announces the first shipment of its new Geodesic EEG System ("GES") 400 series of products for EEG monitoring. The GES 400 platform adds three systems to EGI's established product line and is aimed at filling the needs of a broad range of research and clinical customers, from entry level EEG through to the most advanced, dense array EEG ("dEEG") imaging.

The GES 400 series comprises:

·; GES 400 - the foundation product providing the highest level of features including future expandability of functionality and a platform for multimodal imaging, such as the use of EEG alongside functional MRI and MEG to enhance diagnostic and imaging capabilities.

·; GES 410 - providing a higher sampling rate for specialised research and clinical applications.

·; GES 405 - a streamlined 32 channel EEG product suited for customers who do not need the very high levels of functionality and imaging of the dEEG product suite, providing EGI technology in a more affordable and easy to use package.

The GES 400 series is based on EGI's new ADAPT amplifier technology platform. The state of the art hardware components allow faster flow of information throughout the amplifier, increased bandwidth and synchronous acquisition from multiple amplifiers enabling the simultaneous review of brain activity from two or more people. Each of the GES 400 systems carries the CE Mark with additional regulatory clearances anticipated to allow sale for medical use in the US later this year and in other major markets such as Japan and China next year.

Don Tucker, PhD, Chairman and CEO, commented: "We continue to meet the evolving needs of our customers through the successful development of the GES 400 platform. The introduction of our ADAPT technology is a significant step towards realising our vision of a fully interconnected neuroscience capability that will allow multiple researchers and clinicians to share data and collaborate as never before, all with the goal of improving the understanding and health of the human brain."

For more information contact:

About EGI

Founded in 1992, EGI designs, develops and commercialises a range of non-invasive neurodiagnostic products used to monitor and interpret brain activity based on its proprietary dense array electroencephalography ("dEEG") platform technology. The Company's technology uses up to 256 sensors, providing much higher resolution brain activity data compared to conventional 8 or 16 channel EEG and is used in medical, clinical and research settings in a diverse range of applications including important areas such as the diagnosis and monitoring of epilepsy, neurosurgical planning, sleep assessment, and many others.

EGI's dEEG systems, available in the GES 300 and now the GES 400 lines, capitalize on the Company's unique Hydrocel Geodesic Sensor Net which allows faster, easier, and more convenient placement of many EEG sensors in an even distribution over the entire scalp, providing more accurate and precise diagnosis and measurement. EGI's technology is now widely used in neuroscience research laboratories and is becoming more commonly used in clinics, care centers, and hospitals around the world. Data is measured and visualised using EGI's proprietary amplifier technology and software, providing a complete, advanced, high-resolution EEG platform. The Company's products are compatible with multiple diagnostic and imaging technologies, including magnetic resonance (MR) imaging, functional MRI (fMRI), and magneto-encephalography (MEG).

About EGI's ADAPT Amplifier Platform

The ADAPT technology includes on-board computing within the amplifier through an embedded processor, internal data storage, and wireless capabilities enabling remote software upgrades, greatly streamlining the delivery of new features to customers, and reducing the footprint required by the EEG system. In the future, the on-board computing capabilities will help enable a fully networked neuroscience laboratory or clinic, where autonomous acquisition and storage of EEG data can be linked and streamed directly to a secure network. Here, review stations will be able to monitor the data stream in real time and a common laboratory storage system can coordinate data acquisition from multiple units.

In April 2013 EGI commenced trading on the London Stock Exchange AIM market under the symbol EGI.L. See www.egi.comfor more information on the Company.